Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 176Colorectal Neoplasms 153Rectal Neoplasms 122Stomach Neoplasms 112Pancreatic Neoplasms 60Neoplasm Metastasis 60Colonic Neoplasms 42Triple Negative Breast Neoplasms 34Neoplasms 29Esophageal Neoplasms 28Cholangiocarcinoma 17Biliary Tract Neoplasms 17Nasopharyngeal Carcinoma 16Gallbladder Neoplasms 16Carcinoma, Hepatocellular 16Adenocarcinoma 16Locally Advanced Rectal Cancer 15Squamous Cell Carcinoma of Head and Neck 10Head and Neck Neoplasms 10Esophageal Squamous Cell Carcinoma 10Brain Neoplasms 10Bile Duct Neoplasms 10Adenocarcinoma Of Esophagus 10Liver Neoplasms 9Gastrointestinal Neoplasms 9Breast Neoplasms, Male 9Neuroendocrine Tumors 7Colorectal Cancer Metastatic 7Carcinoma, Renal Cell 7Ovarian Neoplasms 6

Interventions

Oxaliplatin 2sintilimab 1irinotecan sucrosofate 1dostarlimab 1XELOX 1Neoadjuvant Therapy 1Immune Checkpoint Inhibitors 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Rectal Cancer (LARC) × Capecitabine × Clear all
NCT07381777 2026-02-02

IMMUNOSTAR

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Not yet recruiting
270 enrolled
Gastrointestinal

Locally Advanced Rectal Cancer (LARC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡